

# AAiPS

## Newsletter

---

Vol. 29 Issue 1

Jan 2019 – June 2019

---



AMERICAN ASSOCIATION  
OF INDIAN PHARMACEUTICAL SCIENTISTS

P.O. Box 189  
Mount Freedom, NJ 07970

---



AAiPS  
P.O. Box 189  
Mount Freedom  
NJ 07970

### **INSIDE THIS ISSUE**

- *President's Message*
- *2018 Annual Meeting coverage*
- *Pharmaceutical News from India*
- *Classified Column*
- *Sponsors*

Newsletter Editor: **Raghu Kasu**  
Editorial Board, Mike Yelvigi, Sampath Singhvi

**PRESIDENT'S MESSAGE**

Dear Members,

Greetings and Best Wishes for spring of 2019. Hope you are enjoying the change to spring like weather after cold winter.

AAiPS has a strong following and great root. We should all be proud of our membership for their involvement in this and the parent organization (AAPS). In addition, to continuing our great tradition of regional meetings and one full meeting at the AAPS annual meeting, our goal will be to expand one of our regional meeting. We should continue to work hard on both bringing in new members and renewing the annual members and finding a way to keep the interest of our life members. Our goal will be to bring a little more energy and structure to the membership and sponsorship committee and make the AAiPS website more accessible and informative for the members.

In keeping with our goal to grow and increase diversity within AAiPS we have undertaken a few initiatives. Firstly, we have decided to continue with the same (6) number of student awards to

give greater opportunities to the student community to get to the AAPS annual meeting and present their research work. Secondly, we have re-instituted the Young Educator Award to be awarded for recognizing the young deserving educator from India

I am very grateful to both new and old sponsors for their support for making 2018 a great year. Our goal will be, in addition to retaining the present sponsors, to bring back the old sponsors whom we have a lost over the past several years and adding some new sponsors to make the organization strong. Finally, I would thank the very hardworking and dedicated executive and working committees for their continued support. The executive committee is also looking for volunteers to help in several of AAiPS committees. I urge you to please come forward. Please feel free to contact me with your suggestions and ideas.

Regards  
Vijai Kumar  
President

**QUOTE OF THE QUARTER**

***“Patience and Perseverance overcome mountains of difficulties-Mahatma Gandhi”***

## 2018 Annual Meeting Update

### Washington, DC- November, 2019

On Nov 6, 2018, AAiPS Annual Meeting was held at the Marriott Marquis in Washington DC. The Chief Guest of Honor was Ms Vinita Gupta CEO of Lupin Limited.



Ms Gupta gave an excellent presentation regarding the growth of Lupin over the last 50 years. How the company was started with singular goal to provide medicine for the masses. The company was started by Vinita's father Dr. Desh Bandhu Gupta in 1968, 50 years ago and Dr. Desh Bandhu Gupta was our Guest of Honor at AAiPS annual meeting- October 30, 1996 held at Sheraton Seattle Hotel & Towers, Seattle, almost 22 years ago and whose presentation were fondly remembered by some of the AAiPS members who had attended his presentation. Vinita Gupta recalled learning about the business from her father.



Vinita discussed the current trends in US Pharma Industry and then presented Lupin's Overview and strategic vision. Afterwards she had an excellent QA session. Ms Gupta also decided to honor her father and dedicate AAiPS 2019 Young Educator Award to be presented in memory of her father.



The talk was followed by recognition of the AAiPS student award winners. The students were awarded a certificate of recognition and a \$ 500 cheque.



## AAiPS Events-2019



AAiPS First Regional Meeting 2019 in New Jersey was held on April 25, 2019. Topic for the day was “A CDMO Perspective on the Formulation of Complex Dosage Forms” by Dr. Robert W. Lee, PhD.

AAiPS had conducted joint meeting with TiE New Jersey at Nevakar Inc, Bridgewater NJ on May 29th, 2019 on “ Leadership insights from entrepreneur and intrapreneur in Healthcare industry” .

### India News

#### **Professor Mrs. M.R. Baichwal Visiting Fellowship in Pharmaceutical Science & Technology Award at UDCT (Institute of Chemical Technology, Mumbai):**

The American Association of Indian Pharmaceutical Scientists (AAiPS), New Jersey, created this endowment in the year 2000 at UDCT, Mumbai for honoring a distinguished scientist every year to interact with the faculty and students of the UDCT. There is a token honorarium associated with the award which includes travel and all expenses such as boarding, incidental expenses;

**2019 Award Winner:** Dr. Santylal Daya, Faculty of Pharmacy, Rhodes University, Grahamstown South Africa.

This was followed by other AAiPS Awards ceremony. The Outstanding Achievement Award was presented to Dr. Mohan Kabadi, and the Distinguished Scientist Award was presented to Dr. Laxmi Raghavan, Dr. Mehul Mehta, Dr. Ravi Kovi, and Dr. Narasimha Murthy. Each recipient was recognized and presented with a plaque.



This year again the AAiPS annual meeting was on Diwali day and we recognized this by besides having a great dinner catered by IndAroma we also had the Diwali sweets for each attendee. which gave a nice festive touch to the meeting. Looking forward to seeing you all at AAiPS in San Antonio next year Be There!

## PHARMA NEWS

### **Aurobindo Pharma buys Sandoz's US business in \$900 million deal**

Its largest overseas pharma transaction, Aurobindo Pharmaceuticals has announced the acquisition of Sandoz's generic business in the US for \$900 million. The deal gives the Hyderabad-based company access to Sandoz's portfolio of oral solids and dermatology drugs and makes it the second-largest generic player in the US based on prescriptions.

[www.business-standard.com](http://www.business-standard.com).

### **Glenmark opens \$100M plant in North Carolina, its first in U.S.**

Glenmark was among a wave of drugmaker that decided having U.S. manufacturing was a good hedge when FDA crackdowns on facilities in India. The 100,000-square-foot facility is designed to produce not only a variety of fixed dose formulations in tablets and capsules but also vials and prefilled syringes as well as ampoules for inhaled formulations, the drugmaker said. The company expects to build employment there well beyond the 168 workers currently on site. Glenmark won its first Abbreviated New Drug Application for the Monroe, North Carolina, plant in June 2018.

[Fiercepharma.com](http://Fiercepharma.com)

### **Indian pharma companies grab 290 final ANDA approvals from US FDA in 2018**

Indian Pharmaceutical companies and their subsidiaries have established strong presence in US during last couple of years with higher ANDA approvals. The loss of patent exclusivity and cost cutting measures adopted by several nations pushed the demand for generic segment. Indian pharma companies enhanced their investments in research

and development (R&D) and successfully received higher approvals from US FDA during last decade. Out of total 5,350 ANDA approvals between 2009 to 2018, Indian companies have secured 34.4% of these approvals and received total 1,842 ANDA final approvals. Further, out of total 1,310 tentative approvals, Indian companies grab 500 tentative approvals from US FDA which worked out to over 38.2%.

[www.pharmabiz.com](http://www.pharmabiz.com)

### **Bharat Biotech eyes largest rabies vaccine maker tag after GSK deal.**

After the deal with GSK, Bharat Biotech will have a total capacity of 25 million doses, against the nation's demand of 35 million doses Hyderabad-based vaccine company Bharat Biotech's co-founder Krishna Ella, the scientist-turned entrepreneur, harbours hopes of making a major dent in the Indian and global vaccine space.

[Business standard.com](http://Business standard.com)

### **Pfizer to shut Chennai, Aurangabad units; 1,700 workers likely to be affected.**

U.S.-based pharma major Pfizer said it plans to shut down its manufacturing units in Chennai and Aurangabad in the current fiscal due to very significant long-term loss of product demand. The closure is expected to impact nearly 1,700 workers.

### **Valsartan recalls raise blood pressure of Indian drug makers.**

A probable carcinogenic impurity found in the pill Valsartan, commonly prescribed medication to treat hypertension, is giving generic drug makers high blood pressure. To be sure, Aurobindo, Torrent Pharma, Hetero, Mylan, Teva and Sandoz had multiple recalls of medications containing Valsartan.

[Moneycontrol.com](http://Moneycontrol.com)

### **Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company**

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that Alessandro Riva, MD, will join its new innovation company as Chief Executive Officer. Alessandro is currently Executive Vice President, Oncology Therapeutics and Cell Therapy for Gilead Sciences.

[www.prnewswire.com](http://www.prnewswire.com)

### **Aceto Strikes Deal To Offload Rising For Just US\$15m**

Aceto has struck a deal to sell its Rising Pharmaceuticals unit and related businesses to Shore Suven Pharma for US\$15 million. The agreement comes shortly after Aceto agreed to divest its chemicals business assets for US\$338 million after filing Chapter 11 bankruptcy petitions in the US. Shore Suven Pharma Inc is a joint venture between Suven Life Sciences and Shore Pharma Investments LLC a firm founded by Aceto director Vimal Kavuru "to acquire generic drug assets".

[generics.pharmaintelligence.informa.com](http://generics.pharmaintelligence.informa.com)

### **AbbVie Strikes Deal with Lupin for Blood Cancer Program.**

AbbVie closed out 2018 by striking a nearly \$1 billion licensing deal for India-based Lupin Ltd.'s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.

[www.biospace.com](http://www.biospace.com)

### **Zydus Cadila Gets First Patch Approval Amid Push Into US**

A generic rival to Novartis' Exelon extended-release treatment for dementia marks Zydus Cadila's first transdermal patch approval in the US, furthering the Indian firm's strategy of targeting more complex delivery forms.

[generics.pharmaintelligence.informa.com](http://generics.pharmaintelligence.informa.com)

### **Domestic market growth helping Indian pharma companies offset pricing pressure in US.**

Rising revenues in the domestic market has helped Indian pharma companies counterbalance the ongoing pricing pressure on generic drugs in the US in the financial year ended March 31, Fitch Ratings said Monday. The US and India are the two key markets served by Indian pharmaceutical companies, which sell predominantly generic drugs, Fitch Ratings said in a statement.

"By contrast, growth in the US market remained subdued for many Indian drugmakers, as consolidation of pharma distributors and a faster pace of approvals of new generic drugs by the US Food and Drug Administration (USFDA) has resulted in continued pressure on generic drug pricing over the last few years," the statement said.

<https://health.economictimes.indiatimes.com/>

## Obituary



# Dr. Patrick P. DeLuca

## Obituary

Passed away on Wednesday, May 22, 2019 with his wife Judith, his six children, their spouses and numerous grandchildren at his side.

He was born on September 7, 1935 in Scranton, PA, to the late Patsy and Mary DeLuca. He was predeceased by his brother Sam DeLuca. He is survived by his children, Dr. Paul (Denise) DeLuca, Tom (Terry) DeLuca, Patrick (Patricia) DeLuca, Don (Scott) DeLuca, Dr. Michelle DeLuca (Darrell) Fraley, Michael (Myra) DeLuca, his brother Neal (Florence) DeLuca, Long Island, NY and sister in law Regina DeLuca, Niagara Falls, NY. He leaves a loving family legacy of 12 grandchildren and 7 great grandchildren, blessed by the newest child on May 22.

He devoted his life to God and was a brilliant servant shepherd to his wife, family, relatives, friends, faith communities, foreign and domestic students and those in need. He left the corporate Pharmaceutical Industry, moving his family to Lexington in 1970, joining the faculty at the University of Kentucky, College of Pharmacy where he held Administrative positions and served as an Associate Dean. His research work and teachings helped him to secure numerous patents. He has a lasting influence to his students, helping the college's faculty to national prominence. He secured help and support for the college to build 2 new instructional and research facilities.

His life accomplishments began with his Doctorate Degree from the University of Temple where he began much of his life's research. He held the office of President of APHA and AAPS as well as editor of the AAPS scientific journal. He received an honorary doctorate degree from the University of Perugia in Perugia, Italy.

His talented expertise allowed many opportunities to consult on pharmaceutical, equine, and military projects and legal cases. The most memorable mission trip was to Ghana, Africa where he introduced the game of baseball to the children and procured all necessary equipment. In Lexington, Dr. DeLuca was a founder of "Faith Pharmacy" helping to consult and secure free medications to Lexington's underserved. He lived his life for Christ. He was always charitable with his time, talent and monetary gifts. His wife and family were his greatest life's rewards.

## **AAiPS Research Awards: 2019**

The **American Association of Indian Pharmaceutical Scientists (AAiPS)** is pleased to announce the availability of **SIX** awards for the graduate students in Pharmaceutical Sciences. Applicants in pharmaceutical sciences should submit their research findings. Applications for consideration to the regulatory and clinical science should be focused on the drug regulation and practice and science in the clinical setting. **FOUR** awards will be given to the students of Indian heritage and **TWO** are open to all graduate students. The awards will be presented at the AAiPS Annual Meeting banquet at San Antonio, Texas.

### **Criteria for submission:**

Interested graduate students should submit no more than an 800 words summary of their research findings and up to two (2) images. The format should include Title, Author/s, Affiliation, Purpose, Methods, Results and Conclusion. Title, author/s and affiliation would not be counted towards 800 words.

At the end of your abstract, please include contact details (primary author's name, email and phone followed by major advisor's name, email and phone)

All applicants **must** present their research findings at the 2019 Annual meeting of the American Association of Pharmaceutical Scientists (AAPS). **Abstract should have been accepted by AAPS.**

➤ Please include category on top of your abstract. You can apply to any one categories from the five listed below. See the format below for writing your abstract.

**Section:**  
**Title:**  
**Authors name:**  
**Affiliation:**  
**Purpose:**  
**Methods:**  
**Results:**  
**Conclusion:**  
**Contact details:**

**Categories to submit abstracts:**

1. **Drug Delivery/Pharmaceutical Technologies:** All topics related to formulation, physical pharmacy, biotherapeutics, biotechnology, biosimilars, drug discovery and manufacturing/manufacturing Science and Engineering.
2. **Analysis and Pharmaceutical Quality:** All topics related to Dissolution Technologies, In Vivo-In Vitro Relationships/Correlations, Method Development and Validation, Electrophoresis, High-throughput Analysis, Hyphenated Methods—Small Molecule (e.g., GC-MC, LC-MS, etc.), PK Samples, Theoretical and Statistical Aspects of Method Validation.
3. **Pharmacokinetics, Pharmacodynamics, and Drug Metabolism:** All topics related to biopharmaceutics, bioavailability, First Pass Effects / Drug Absorption (Food Effects, Formulation Effects), Drug Interactions, PK and PK/PD Modeling, Tissue Distribution and Microdialysis, Toxicokinetics / Toxicology, Transporters.
4. **Clinical Pharmacology, Transitional Research and Biomarkers:** All topics related to clinical trials, pharmoeconomics, pharmacotherapy, and therapeutic drug monitoring and transitional research.
5. **Regulatory Affairs:** All topics related to regulatory affairs like cGMP, CMC, regulations/guidance, ICH guidelines etc.

**Please send your submissions by Friday, September, 6<sup>th</sup> 2019 to:**

**Prof. Hardeep Saluja**

Chair, AAiPS Research Awards Committee  
Southwestern Oklahoma State University  
College of Pharmacy, Weatherford, OK 73096  
Email: hardeep.saluja@swosu.edu  
Office: (580) 774-3727

**For  
Training Programs  
And  
Consulting Needs**

**CONTACT:**

**CHRAI ASSOCIATES, INC.**

**16 BODINE DRIVE, CRANBURY, NJ 08512**

**Voice: (609) 655 2573; Cell: (609) 462-6845**

**Fax: (609) 655 2573; E-mail: [schrai@att.net](mailto:schrai@att.net)**

**PEOPLE ON THE MOVE****ADVERTISEMENT RATES**

The rates of advertisement for the AAiPS newsletter are as follows:

One year (four issues): \$1000 full page,  
\$500 half a page, \$250 quarter page

One time (one issue): \$400 full page,  
\$200 half a page, \$100 quarter page.

Contact: Mukund Yelvigi, myelvigi@hotmail.com

*No advertisements under a quarter page*

**AAiPS THANKS ITS SPONSORS**

*AAiPS thanks the following sponsors for their continued support of this organization.*

**Diamond Sponsors: BASF**

**Gold Sponsors:** Aqualon Inc., Associated Capsules Group, BA Research International, Capsugel, Chrai Associates, Inc., Colorcon, Dow Chemical Company, Evonik, FMC Biopolymer, JRS Pharma, K.W. Tunnell, Co., Mutchler Pharma, Mendel Company, Patheon, Ranbaxy, Rubicon, Seppic, Strides, Thomas Engineering Inc.

**Silver Sponsors:** Drug Delivery Technology, Gattefosse, International Specialty Products. Absorption Systems.

**AAiPS Office Bearers for 2018-2019**

**President:** Vijai Kumar

**Vice President:** Samit Deb.

**Secretary:** Shrikant Bhonsle.

**Treasurer:** Suggy Chrai

**Immediate Past President:** Rina Choksi

**Members-at-large:** Dr. Sampat Singhvi, Mukund “Mike” Yelvigi, Dr. Uday Doshi

**Program Committee:** Dr. Rupa Doshi

**Student Awards and Scholarship:** Dr. Hardeep Saluja

**Communication:** Kalyani Medboyina

**Newsletter: Editor:** Raghu Kasu